Cargando…

Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity

[Image: see text] In tropical and subtropical areas, malaria stands as a profound public health challenge, causing an estimated 247 million cases worldwide annually. Given the absence of a viable vaccine, the timely and effective treatment of malaria remains a critical priority. However, the growing...

Descripción completa

Detalles Bibliográficos
Autores principales: Borba, Joyce V. B., de Azevedo, Beatriz Rosa, Ferreira, Larissa A., Rimoldi, Aline, Salazar Alvarez, Luís C., Calit, Juliana, Bargieri, Daniel Y., Costa, Fabio T. M., Andrade, Carolina Horta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515587/
https://www.ncbi.nlm.nih.gov/pubmed/37744849
http://dx.doi.org/10.1021/acsomega.3c05138
_version_ 1785108979425214464
author Borba, Joyce V. B.
de Azevedo, Beatriz Rosa
Ferreira, Larissa A.
Rimoldi, Aline
Salazar Alvarez, Luís C.
Calit, Juliana
Bargieri, Daniel Y.
Costa, Fabio T. M.
Andrade, Carolina Horta
author_facet Borba, Joyce V. B.
de Azevedo, Beatriz Rosa
Ferreira, Larissa A.
Rimoldi, Aline
Salazar Alvarez, Luís C.
Calit, Juliana
Bargieri, Daniel Y.
Costa, Fabio T. M.
Andrade, Carolina Horta
author_sort Borba, Joyce V. B.
collection PubMed
description [Image: see text] In tropical and subtropical areas, malaria stands as a profound public health challenge, causing an estimated 247 million cases worldwide annually. Given the absence of a viable vaccine, the timely and effective treatment of malaria remains a critical priority. However, the growing resistance of parasites to currently utilized drugs underscores the critical need for the identification of new antimalarial therapies. Here, we aimed to identify potential new drug candidates against Plasmodium falciparum, the main causative agent of malaria, by analyzing the transcriptomes of different life stages of the parasite and identifying highly expressed genes. We searched for genes that were expressed in all stages of the parasite’s life cycle, including the asexual blood stage, gametocyte stage, liver stage, and sexual stages in the insect vector, using transcriptomics data from publicly available databases. From this analysis, we found 674 overlapping genes, including 409 essential ones. By searching through drug target databases, we discovered 70 potential drug targets and 75 associated bioactive compounds. We sought to expand this analysis to similar compounds to known drugs. So, we found a list of 1557 similar compounds, which we predicted as actives and inactives using previously developed machine learning models against five life stages of Plasmodium spp. From this analysis, two compounds were selected, and the reactions were experimentally evaluated. The compounds HSP-990 and silvestrol aglycone showed potent inhibitory activity at nanomolar concentrations against the P. falciparum 3D7 strain asexual blood stage. Moreover, silvestrol aglycone exhibited low cytotoxicity in mammalian cells, transmission-blocking potential, and inhibitory activity comparable to those of established antimalarials. These findings warrant further investigation of silvestrol aglycone as a potential dual-acting antimalarial and transmission-blocking candidate for malaria control.
format Online
Article
Text
id pubmed-10515587
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-105155872023-09-23 Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity Borba, Joyce V. B. de Azevedo, Beatriz Rosa Ferreira, Larissa A. Rimoldi, Aline Salazar Alvarez, Luís C. Calit, Juliana Bargieri, Daniel Y. Costa, Fabio T. M. Andrade, Carolina Horta ACS Omega [Image: see text] In tropical and subtropical areas, malaria stands as a profound public health challenge, causing an estimated 247 million cases worldwide annually. Given the absence of a viable vaccine, the timely and effective treatment of malaria remains a critical priority. However, the growing resistance of parasites to currently utilized drugs underscores the critical need for the identification of new antimalarial therapies. Here, we aimed to identify potential new drug candidates against Plasmodium falciparum, the main causative agent of malaria, by analyzing the transcriptomes of different life stages of the parasite and identifying highly expressed genes. We searched for genes that were expressed in all stages of the parasite’s life cycle, including the asexual blood stage, gametocyte stage, liver stage, and sexual stages in the insect vector, using transcriptomics data from publicly available databases. From this analysis, we found 674 overlapping genes, including 409 essential ones. By searching through drug target databases, we discovered 70 potential drug targets and 75 associated bioactive compounds. We sought to expand this analysis to similar compounds to known drugs. So, we found a list of 1557 similar compounds, which we predicted as actives and inactives using previously developed machine learning models against five life stages of Plasmodium spp. From this analysis, two compounds were selected, and the reactions were experimentally evaluated. The compounds HSP-990 and silvestrol aglycone showed potent inhibitory activity at nanomolar concentrations against the P. falciparum 3D7 strain asexual blood stage. Moreover, silvestrol aglycone exhibited low cytotoxicity in mammalian cells, transmission-blocking potential, and inhibitory activity comparable to those of established antimalarials. These findings warrant further investigation of silvestrol aglycone as a potential dual-acting antimalarial and transmission-blocking candidate for malaria control. American Chemical Society 2023-09-05 /pmc/articles/PMC10515587/ /pubmed/37744849 http://dx.doi.org/10.1021/acsomega.3c05138 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Borba, Joyce V. B.
de Azevedo, Beatriz Rosa
Ferreira, Larissa A.
Rimoldi, Aline
Salazar Alvarez, Luís C.
Calit, Juliana
Bargieri, Daniel Y.
Costa, Fabio T. M.
Andrade, Carolina Horta
Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity
title Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity
title_full Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity
title_fullStr Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity
title_full_unstemmed Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity
title_short Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity
title_sort transcriptomics-guided in silico drug repurposing: identifying new candidates with dual-stage antiplasmodial activity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515587/
https://www.ncbi.nlm.nih.gov/pubmed/37744849
http://dx.doi.org/10.1021/acsomega.3c05138
work_keys_str_mv AT borbajoycevb transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT deazevedobeatrizrosa transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT ferreiralarissaa transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT rimoldialine transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT salazaralvarezluisc transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT calitjuliana transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT bargieridaniely transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT costafabiotm transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity
AT andradecarolinahorta transcriptomicsguidedinsilicodrugrepurposingidentifyingnewcandidateswithdualstageantiplasmodialactivity